Berget C, Akturk HK, Messer LH, et al. - This study sought to present real-world hybrid closed-loop (HCL) use and glycemic outcomes across the lifespan and distinguish a clinical threshold for HCL use associated with meeting the internationally recommended target of 70% sensor glucose time in range (time in range [TIR]; 70-180 mg/dL). Mixed models were used to analyze MiniMed 670G HCL use and glycemic outcomes in 276 people with type 1 diabetes from four age groups: youth (< 18y), young adults (18-25y), adults (26-49y), and older adults (≥ 50y) for one year. The minimum percent HCL use associated with meeting the TIR goal of 70% was distinguished using ROC analysis. The results showed that HCL use of >70% may be a useful target for clinicians to use to assist persons with diabetes in attaining glycemic goals. The findings demonstrated that youth may struggle with HCL use more than adults and require clinical intervention to help sustain HCL use across time.